These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7520247

  • 1. Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals.
    Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA.
    AIDS; 1994 May; 8(5):575-81. PubMed ID: 7520247
    [Abstract] [Full Text] [Related]

  • 2. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study.
    Thewes M, Elsner E, Wessner D, Engst R, Ring J.
    Int J Dermatol; 2000 Mar; 39(3):188-91. PubMed ID: 10759957
    [Abstract] [Full Text] [Related]

  • 3. Spindle cells isolated from Kaposi's sarcoma-like lesions of BKV/tat-transgenic mice co-express markers of different cell types.
    Cavallaro U, Gasparini G, Soria MR, Maier JA.
    AIDS; 1996 Sep; 10(11):1211-9. PubMed ID: 8883582
    [Abstract] [Full Text] [Related]

  • 4. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F, D'Alessio S, Serratì S, Pucci M, Del Rosso A, Benelli R, Ferrari N, Noonan DM, Albini A, Fibbi G, Del Rosso M.
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG.
    Cancer; 1996 Mar 15; 77(6):1079-88. PubMed ID: 8635127
    [Abstract] [Full Text] [Related]

  • 8. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H, Ooya K.
    J Oral Pathol Med; 2007 Sep 15; 36(8):488-94. PubMed ID: 17686008
    [Abstract] [Full Text] [Related]

  • 9. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK, Gertz RE, Ivins CM, Kacinski BM.
    Cancer; 1995 Apr 01; 75(7):1627-33. PubMed ID: 8826920
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Horch HH.
    Mund Kiefer Gesichtschir; 2004 May 01; 8(3):180-90. PubMed ID: 15138856
    [Abstract] [Full Text] [Related]

  • 11. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ.
    Cancer Res; 2000 Oct 15; 60(20):5839-47. PubMed ID: 11059781
    [Abstract] [Full Text] [Related]

  • 12. Sustained angiogenesis enables in vivo transplantation of mucocutaneous derived AIDS-related Kaposi's sarcoma cells in murine hosts.
    Mallery SR, Pei P, Kang J, Zhu G, Ness GM, Schwendeman SP.
    Carcinogenesis; 2000 Sep 15; 21(9):1647-53. PubMed ID: 10964095
    [Abstract] [Full Text] [Related]

  • 13. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
    Billottet C, Janji B, Thiery JP, Jouanneau J.
    Oncogene; 2002 Nov 21; 21(53):8128-39. PubMed ID: 12444548
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 15. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 01; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 16. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
    Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS.
    Clin Cancer Res; 2007 Jul 15; 13(14):4051-60. PubMed ID: 17634529
    [Abstract] [Full Text] [Related]

  • 17. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
    Borgfeldt C, Hansson SR, Gustavsson B, Måsbäck A, Casslén B.
    Int J Cancer; 2001 May 15; 92(4):497-502. PubMed ID: 11304683
    [Abstract] [Full Text] [Related]

  • 18. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 01; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 20. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2.
    Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson WG.
    AIDS; 1994 Sep 01; 8(9):1237-44. PubMed ID: 7528513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.